Daniel Donauer is an attorney in the firm’s Zurich office and a member of the Product Regulation, Intellectual Property and Litigation & Arbitration practice groups.
Daniel Donauer’s practice focuses on matters in the life sciences sector. In this context, he advises his clients on both regulatory and litigation issues of health care and medical law, in particular on product regulation and product implementation for pharmaceuticals and medicinal products, medical devices, food, alcohol and tobacco products, consumer goods (i.e., cosmetics, human contact articles, etc.) as well as chemicals, and handles matters in the area of advertising law. In addition, he advises and litigates in intellectual property matters. A particular focus of his advice lies in the area of health insurance law as well as in the area of care law. Furthermore, he assists clients with medical law matters in the area of human research, reproductive medicine or genetic engineering and advises on medical professionals’ law as well as physician and patient law.
Daniel Donauer is author and editor of legal books and treatises. He regularly publishes on topics related to health and medical law as well as intellectual property law.
Daniel Donauer studied at the University of Bern (BLaw/MLaw) and in a special program focused on health law at the University of Washington in the USA (LL.M. – Academic Excellence Award for the best degree in his year). In 2021, he completed a continuing education program in medicine law at the University of Zurich (CAS, Medicine Law). He furthermore obtained his doctorate (Dr. iur) from the University of Lucerne in 2018.
Prior to being admitted to the bar in the Canton of Zurich in 2016, he worked as a legal intern at the Civil and Criminal Court as well as at a law firm in the Canton of Solothurn. Subsequently, he practiced at the Department of Economic and Home Affairs of the Canton of Aargau. Before being admitted to the bar, he also worked as a legal intern at one of Switzerland’s leading law firms in Zurich. After completing his legal internship, Daniel Donauer worked as a research assistant at the Chair of the Law of Obligations and Civil Procedure at the University of Lucerne.
Prior to joining MLL, Daniel Donauer worked as an attorney specializing in health and medical law at one of the leading law firms in Zurich.
He is fluent in German and English.
Rankings & Awards
Education & Admission
- University of Zurich, CAS Medical Law (2021)
- University of Washington, USA (Health Law), LL.M. (2020)
- University of Lucerne, Dr. iur. (2018)
- Admitted to the bar in Switzerland (2016)
- University of Berne, MLaw (2013)
Memberships and public offices
- Zurich Bar Association (ZAV)
- Swiss Bar Association (SAV)
- Die Zulässigkeit von Cannabis in kosmetischen Mitteln | 27.06.2022
- Medical Cannabis & Cannabinoid Regulation 2022 Switzerland – Law & Practice and Trends & Developments | 20.06.2022
- Neuoptierung bei Verlust des Versicherungsverhältnisses im Bereich der OKP | 10.06.2022
- Regulierungsvorgaben für die umweltbezogene Produkteanpreisung | 02.05.2022
Medical Cannabis & Cannabinoid Regulation 2022 Switzerland – Law & Practice and Trends & DevelopmentsChambers and Partners, Global Practice Guides, Medical Cannabis & Cannabinoid Regulation, 20 June 2022
dRSK, 10. Juni 2022
- Daniel Donauer
- Anna Pellizzari
Jusletter, 2. Mai 2022
- Daniel Donauer
- Anna Pellizzari
Revision: Cannabis Regulation – New Authorization Mechanism for Dealing With Medical Cannabis
On 1 August 2022, not only the annual national holiday could be celebrated extensively in Switzerland. Particularly noteworthy is also the entry into force of the new requirements for the regulation of medical cannabis.
Cannabis was qualified as a prohibited narcotic in Switzerland until the end of summer 2022 – without further specification in relation to a medical application. Accordingly, the cultivation, importation, production, and marketing of cannabis required an exemption permit from the Federal Office of Public Health (FOPH).More
Legal Framework for the Use of Psychedelics in Switzerland
Just in time for summer, the miniseries «How to Change Your Mind» will be launched in July on the Netflix streaming platform. In this documentary series, author Michael Pollan and Co. analyse the history and applications of psychedelic substances such as LSD, psilocybin, MDMA and mescaline. According to experts, research with psychedelics (also known as hallucinogens) or related substances will increase worldwide in the coming years. The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years. The legal framework regarding the use of psychedelics in patients is very pragmatic in Switzerland and unique internationally. Switzerland is a leader in the research and use of psychedelics in psychiatry and is considered an innovation driver in this field. Nevertheless, the regulatory hurdles for researchers and patients are still extremely high. In this article we elaborate on the requirements under which psychedelics may be used in Switzerland today.
The Swiss Federal Supreme Court affirms interest in bringing an action for annulment with respect to a Central Attack under the Madrid System
In its decision 4A_97/2020 of August 5, 2020, the Swiss Federal Supreme Court addressed the question of whether the interest in bringing an action for annulment concerning a basic trademark can be affirmed due to the legal consequences inherent to an approval of such claims under the institute of the so-called Central Attack.More